SecBot SecBot

BYSI

BeyondSpring Inc.
Nasdaq· Pharmaceutical Preparations· CIK 0001677940 Biotech & Drug Discovery
$0.4600 +0.03 (+6.73%)
Oct 26 4:00 PM ET · prev $0.4310
Market cap
$18.3M
Nano cap
Next earnings
Nov 10
in 14 days
1 year
−75.4%
from $1.87 · Oct 27
30 days
−58.9%
from $1.12
52-week range
$0.4310–2.35
−80% from high · low Oct 23
Avg volume 20D
185.5K
Sep 29 spike 2.42M
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read BEARISH 8 reports · 90 days
Balance 3 bearish · 0 bullish · 2 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 5/8 ·Next Earnings date, Nov 10, 2026
Strongest BEARISH BeyondSpring received a Nasdaq deficiency notice on September 29, 2026, for failing to maintain a minimum…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 0 trimmed or exited.

  • TrendDOWNTREND

    32% below its 50-day average. New closing low $0.4310 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGDOUBLED63,032$110.3K
SIMPLEX TRADING, LLCADD1,165$2.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action May 2023
Recent actions
DateFirmActionRating
May 2, 2023Baird
MAINTAIN
MAINTAINOutperform
Dec 2, 2021Jefferies
DOWNGRADE
DOWNGRADEHold
Dec 2, 2021B of A Securities
DOWNGRADE
DOWNGRADEUnderperform
Dec 1, 2021HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral
Sep 20, 2021HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Sep 9, 2021Baird
INITIATE
INITIATEOutperform

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jul 1, 2026
Qiu Min
Chief Executive Officer
AWARD100,000 sh
Jul 1, 2026
Majeti Jiangwen
Director
AWARD100,000 sh
Apr 1, 2026
Xu Sihai
Director
AWARD18,689 sh
Apr 1, 2026
Fabbio Patrick
Director
AWARD22,165 sh
Apr 1, 2026
Huang Lan
Chief Executive Officer
AWARD11,514 sh
Apr 1, 2026
Kirkby Matthew
Director
AWARD23,902 sh
Apr 1, 2026
Lu Yingjuan June
Chief Scientific Officer
AWARD17,840 sh
Apr 1, 2026
Delaney Brendan
Director
AWARD20,427 sh

Earnings setup

Estimates
Nov 10
reports in 14 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Aug 13, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 6, 2026 SEC
BeyondSpring completed the sale of its Chinese subsidiary (Bulin) to Biolin Investment Limited on September 30, 2026…
8-K — Impact 6/10
Oct 2, 2026 SEC
BeyondSpring received a Nasdaq deficiency notice on September 29, 2026, for failing to maintain a minimum $35 million…
8-K — Impact 8/10
Sep 29, 2026 SEC
BeyondSpring entered into a definitive agreement to sell its wholly owned subsidiary (which indirectly holds a 57.97%…
8-K — Impact 6/10
Sep 24, 2026 Listing status
Listing Status: BYSI — Deficient (was Normal)
BeyondSpring, Inc. - Ordinary Shares | Nasdaq Financial Status Indicator N → D
Jul 1, 2026 Insider
Qiu Min was granted 100,000 shares
Chief Executive Officer
Jul 1, 2026 Insider
Majeti Jiangwen was granted 100,000 shares
Director
Jun 30, 2026 Inst.
UBS Group AG — DOUBLED
63,032 shares ($110.3K)
Jun 30, 2026 Inst.
SIMPLEX TRADING, LLC — ADD
1,165 shares ($2.0K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
BYSI Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Sep 24, 2026
Listing
Listing Status: BYSI — Deficient (was Normal)
BeyondSpring, Inc. - Ordinary Shares | Nasdaq Financial Status Indicator N → D
Sep 4, 2026
Earnings date
BYSI Q2 2026 Earnings Scheduled — 2026-09-04
Aug 14, 2026
Earnings
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on…
Aug 14, 2026
Short interest
Short Interest: BYSI up 22% to 2.7M shares
Settlement 2026-08-14 | Days to cover: 1.00 | ≈6.64% of shares outstanding (est.)
Aug 13, 2026
Trading halt
Halt Resumed: BYSI — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-08-13T16:21:49.000Z | Resumed 2026-08-13T16:26:49.000Z

SecBot reports

11 filings · 3 press releases · 0 bullish · 3 bearish · 2 mixed · 6 neutral
All BYSI filing & press-release reports (14)